Skip to main content
 Filing · LD-2 quarterly report Q4 amendment
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Mar 5, 2026
Expenses
$100,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Maryland

Official filing document

 Lobbying activity 3

Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. Pricing proposals such as reference pricing/Most Favored Nations as they relate to access to plasma derived therapies.

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.

 Bills named in this filing 1
  • H.R. 3808
    Medicare IVIG Access Enhancement Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem